Bright Minds Biosciences Inc. (DRUG) — Financial statements
Income statement, balance sheet, and cash flow for Bright Minds Biosciences Inc. — annual and quarterly history with growth and margin analysis.
| Metric (CAD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 11↑839.4% | 1↓76.4% | 5↓59.0% | 12↑92.9% | 6 | |
| General & Administrative Expenses | 2↑52.1% | 1↓32.5% | 2↑4.1% | 2↑37.2% | 1 | |
| Selling & Marketing Expenses | 0.43↑932.8% | 0.04↓65.2% | 0.12↓78.4% | 0.55↓35.2% | 0.85 | |
| SG&A Expenses | 3↑77.5% | 1↓34.3% | 2↓13.8% | 3↑10.5% | 2 | |
| Other Expenses | 0.29↑45.9% | 0.20↑5.6% | 0.19↓23.2% | 0.24 | 0.00 | |
| Operating Expenses | 14↑393.8% | 3↓61.8% | 7↓50.7% | 15↑73.7% | 9 | |
| Total Costs & Expenses | 14↑393.8% | 3↓61.8% | 7↓50.7% | 15↑73.7% | 9 | |
| Operating Results | ||||||
| Operating Income | -14↓393.8% | -3↑61.8% | -7↑50.7% | -15↓73.7% | -9 | |
| Depreciation & Amortization | 0.08↑4.8% | 0.07↑1.3% | 0.07↑1100.1% | 0.01↓99.9% | 9 | |
| EBITDA | -14↓404.1% | -3↑62.4% | -7↑51.1% | -15 | 0.00 | |
| EBIT | -14↓393.8% | -3↑61.8% | -7↑50.7% | -15↓73.7% | -9 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↑4942.5% | 0.03 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 2↑4942.5% | 0.03 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 2↑8104.4% | 0.02↑46.7% | 0.01↑39.8% | 0.01↑136.7% | -0.03 | |
| Income Before Tax | -12↓336.5% | -3↑62.0% | -7↑50.7% | -15↓73.0% | -9 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -12↓336.5% | -3↑62.0% | -7↑50.7% | -15↓73.0% | -9 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -12↓336.5% | -3↑62.0% | -7↑50.7% | -15↓73.0% | -9 | |
| Bottom-Line Net Income | -12↓336.5% | -3↑62.0% | -7↑50.7% | -15↓73.0% | -9 | |
| EPS (Basic) | -1.78↓173.8% | -0.65↑67.2% | -1.98↑67.8% | -6.15↓29.7% | -4.74 | |
| EPS (Diluted) | -1.78↓173.8% | -0.65↑67.2% | -1.98↑67.8% | -6.15↓29.7% | -4.74 | |
| Weighted Average Shares | 7↑59.6% | 4↑15.9% | 4↑50.5% | 2↑37.6% | 2 | |
| Weighted Average Diluted Shares | 7↑59.6% | 4↑15.9% | 4↑50.6% | 2↑37.6% | 2 | |
* All figures in Millions of CAD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.